Triple-negative breast cancer （TNBC） represents a distinct subtype of breast cancer，characterized by unique clinical traits including early lung metastasis，elevated recurrence rates，and diminished survival prospects. Owing to the lack of estrogen receptor，progesterone receptor，and human epidermal growth factor receptor 2 expression，concrete therapeutic targets remain elusive，thereby confining available clinical treatment methods. In the context of advanced TNBC，chemotherapy remains the predominant therapeutic approach. In recent years，with the in-depth study of tumor microenvironment，new immunotherapy targets have been discovered one after another. Thus，immunotherapy-based combined therapy strategies have brought new hope in patients with advanced TNBC.